Abstract
Recent research has yielded a dramatic increase in the number of connections between oncogenesis and the proteins which regulate the cell cycle. Three classes of protein which inhibit the activity of cyclin-dependent kinases (CDKs) have emerged as potential targets for oncogenic inactivation. p16 and related proteins inhibit the cyclin/CDK complexes which regulate the transition from G1 to S phase; numerous studies have revealed that p16 is mutated in most tumor cell lines and in some types of primary tumor. p21/WAF1/Cip1 and the related p27Kip protein inhibit a broader range of cyclin/CDK complexes than p16. Although the absence of p21/WAF1/Cip1 from cyclin/CDK complexes is correlated with cellular transformation, no mutations in this gene have been found in tumors or tumor-derived cell lines. A third class of genes which are potential targets for oncogenic inactivation are the kinases and phosphatases which regulate the activity of cyclin/CDK complexes by phosphorylation and dephosphorylation of the CDK proteins. Disruption of any of these genes would result in loss of normal regulation of cell growth.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- ALL :
-
Acute Lymphoblastic leukemias
- CAK :
-
CDC2-activating kinase
- CDK :
-
Cyclin-dependent kinase
- CDI :
-
CDK inhibitor
- GM :
-
Glioblastoma multiforme
- TGF-β :
-
Transforming growth factor-β
References
Nurse P (1994) Ordering S phase and M phase in the cell cycle. Cell 79:583
Hunter T, Pines J (1994) Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79:573–582
Hannon GJ, Beach D (1994) p15 INK4B is a potential effector of TGF induced cell cycle arrest. Nature 371:257–261
Gaun K-L, Jenkens CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera AG, Xiong Y (1994) Growth suppression by p18, a p16 and p14-related CDK6 inhibitor, correlates with wildtype pRB function. Genes Dev 8:2939–2952
Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J (1991) TAN1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66:649–661
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707
Yeager T, Stadier W, Belair C, Puthenveettil J, Olopade O, Reznikoff C (1995) Increase p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55:493–497
Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ (1995) Reciprocal RB inactivation and p16 INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505–509
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tautigian SU, Stocken E, Day RSI, Johnson BE, Skolnick MN (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440
Nobori T, Miura K, Wu D, Lios A, Takabayashi K, Carson DA (1994) Deletions of the cdk4 inhibitor gene in multiple human cancers. Nature 368:753–756
Cairns P, Mao L, Merio A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Reit P, Blaugrund JE, Sidransky D (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:416–417
Kamb A, Liu Q, Harshman K, Tautigian S (1994) Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:416–417
Spruck CHI, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA (1994) p16 gene in uncultured tumors. Nature 370:183–184
Mcqeen HA, Wyllie AH, Piris J, Foster E, Bird CC (1991) Stability of critical genetic lesions in human colorectal carcinoma xenografts. Br J Cancer 63:94–96
Caldas C, Hahn SA, daCosta LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27–32
Mori T, Miura K, Aoki T, Nishihara T, Mori S, Nakamura M (1994) Frequent somatic mutation of MTS1/CDK41 gene in esophagael squamous cell carcinoma. Cancer Res 54:3396–3397
Yeudall WA, Crawford RY, Ensley JF, Robbins KC (1994) MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 15:2683–2686
Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Deki T, Takahashi T, Takahashi T (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in nonsmall cell lung cancers. Cancer Res 55:514–517
Jin J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKU, Kinzler KW, Vogelstein B (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353–6358
Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OI (1995) Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55:984–988
Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, DeLord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JL, Catovsky D, Dyer MJS (1995) Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 4:893–901
Cayuela JM, Hebert J, Sigaux F (1995) Homozygous MST1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood 4:854
Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, Bauters F, Wattel E, Fenaux P (1995) p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 3:657–663
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan D, Clark WHJ, Tucker MA, Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nature Genet 8:15–21
Kamb et al (1994c) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 8:22–26
El-Deiry WS, Tokino T, Velalescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B (1993) WAF1, a petential mediator of p53 tumor suppression. Cell 75:817–825
Harper JW, Adami GR, Wei N, Veyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805–816
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993a) p21 is a universal inhibitor of cyclin kinases. Nature 366:701–704
Noda A, Ning Y, Venable SF, Periara-Smith OM, Smith JR (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211:90–98
Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 cyclin-dependent kinase inhibitor directly controls DNA replication via interaction with PCNA. Nature 369:574–578
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman JJ, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B (1994) WAF1/Cip1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169–1174
Lowe SW, Ruley HE, Jacks T, Houseman DE (1993) p53-dependent apoptosis modulates the cytotoxcity of anticancer agents. Cell 74:957–967
DiLeonardo A, Linke SP, Clarkin K, Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 8:2540–2551
Pan H, Griep AE (1994) Altered cell cycle regulation in the lens of HPV 16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development. Genes Dev 8:1285–1299
Morgenbesser SD, Williams BO, Jacks T, DePinho RA (1994) p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371:72–74
Caelles C, Heimberg A, Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370:220–223
Xiong Y, Zhang H, Beach D (1993b) Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7:1572–1583
Chedid M, Michieli P, Lengel C, Huppi K, Givol D (1994) A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/Cip1. Oncogene 9:3021–3024
Michieli P, Chedid M, Lin D, Pierce JH, Mercer EW, Givol D (1994) Induction of WAF1/Cip1 by a p53-independent pathway. Cancer Res 54:3391–3395
Steinman RA, Hoffman B, Iro A, Guillout C, Liebermann DA, El Houseini ME (1994) Induction of p21 (WAF1/Cip1) during differentiation. Oncogene 9:3389–3396
Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Inglehart JD, Marks JR (1994) Transforming growth factor 1 can induce Cip1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Diff 5:1301–1307
Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lasser AB (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018–1021
Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olsen EN, Harper JW, Elledge SJ (1995) p53-independent expression of p21 in muscle and other terminally differentiating cells. Science 267:1024–1027
Polyak K, Lee M-H, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitotogenic signals. Cell 78:59–66
Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR, Roberts, JM (1994) Interleukin2-mediated elimination of the p27Kiplcyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570–573
Parker LL, Piwnica-Worms H (1992) Inactivation of the p34cdc2-cyclinB complex by the human WEE1 tyrosine kinase. Science 257:1955–1957
McGowan CH, Russell P (1993) Human WEE1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr 15. EMBO J 12:75–85
O'Connor PM, Ferris DK, White GA, Pines J, Hunter T, Longo DL, Kohn KW (1992) Relationshipas between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Diff 3:43–52
O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, Longo DL, Kohn KW (1993) G2 delay induced by nitrogen mustard in human cells affects cyclinA/cdk2 and cyclinB1/cdc2 kinase complexes differently. J Biol Chem 268:8298–8308
Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G (1993) Phosphorylation and activation of human cdc25C by cdc2-cyclin B and its involvement in the self amplification of MPF at mitosis. EMBO J 12:53–63
Hoffmann I, Draetta G, Karsenti E (1994) Activation of the phosphatase activity of human cdc25A by cdk2-cyclinE dependent phosphorylation at the G1/S transition. EMBO J 13:4302–4310
Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Najima H, Okayama H (1994) Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J 13:1549–1556
Gu Y, Rosenblatt J, Morgan DO (1992) Cell cycle regulation of CDK2 activity by phosphorylation of Thr 160 and Tyr 15. EMBO J 11:3995–4005
Sebastian B, Kakizuka A, Hunter T (1993) Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine 14 and tyrosine 15. Proc Natl Acad Sci USA 90:3521–3524
Poon RYC, Yamashita K, Adamczowski JB, Hunt T, Shuttleworth J (1993) The cdc2-related protein p4OM015 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2. EMBO J 12:3123–3132
Solomon MJ, Harper JW, Shuttleworth J (1993) CAK, the p34cdc2 activating kinase, contains a protein identical to or closely related to p40M015. EMBO J 12:3133–3142
Connell-Crowley L, Solomon MJ, Wei N, Harper JW (1993) Phosphorylation independent activation of human cyclin-dependent kinase 2 by cyclin A in vivo. Mol Biol Cell 4:79–92
Gyuris J, Golemis E, Chertkov H, Brent R (1993) Cdi1, a human G1 and S phase protein phosphatase that associates with cdk2. Cell 75:791–803
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Biggs, J.R., Kraft, A.S. Inhibitors of cyclin-dependent kinase and cancer. J Mol Med 73, 509–514 (1995). https://doi.org/10.1007/BF00198902
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00198902